Page last updated: 2024-12-05

n-nitrosodiethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID14223
CHEMBL ID1334
CHEBI ID82357
SCHEMBL ID1288208
MeSH IDM0062425

Synonyms (74)

Synonym
30yi1289vy ,
bis(beta-hydroxyaethyl)nitrosamin
n-nitrosodiaethanolamin
diaethanolnitrosamin
3-04-00-00721 (beilstein handbook reference)
unii-30yi1289vy
2,2'-(nitrosoimino)diethanol
n-nitrosodiethanolamine
1116-54-7
NCGC00091047-01
n-nitrosodiaethanolamin [german]
diaethanolnitrosamin [german]
nitrosodiethanolamine
bis(beta-hydroxyaethyl)nitrosamin [german]
einecs 214-237-4
n,n-diethanolnitrosamine
nci-c55583
ethanol, 2,2'-(nitrosoimino)bis-
rcra waste no. u173
hsdb 4180
2,2'-iminodi-n-nitrosoethanol
2,2'-nitrosiminodiethanol
rcra waste number u173
diethylamine, 2,2'-dihydroxy-n-nitroso-
diethanolnitrosoamine
bis(beta-hydroxyethyl)nitrosamine
ethanol, n-nitrosoiminodi-
2,2'-(nitrosoimino)bisethanol
brn 1762620
ethanol, 2,2'-nitrosiminodi-
ccris 463
diethanolnitrosamine
nitrosoimino diethanol
n-nitrosoaminodiethanol
n-nitrosobis(2-hydroxyethyl)amine
di-(2-hydroxyethyl)-nitrosamine
ndela
n,n-bis(2-hydroxyethyl)nitrous amide
chebi:82357 ,
CHEMBL1334
n-nitrosodoethanolamine
N0438
NCGC00091047-02
n,n-bis(2-hydroxyethyl)nitrous amid
C19278
cas-1116-54-7
tox21_200283
NCGC00257837-01
dtxsid7021027 ,
dtxcid501027
AKOS006228419
FT-0672944
di-(2-hydroxyethyl)nitrosamine
n-nitrosodiethanolamine [mi]
n-nitrosodiethanolamine [hsdb]
trolamine impurity c [ep impurity]
n-nitrosodiethanolamine [iarc]
nitrosodiethanolamine, n-
SCHEMBL1288208
bis(.beta.-hydroxyaethyl)nitrosamin
bi(2-hydroxyethyl)nitrosoamine
bis(.beta.-hydroxyethyl)nitrosamine
YFCDLVPYFMHRQZ-UHFFFAOYSA-N
W-109638
n-nitrosodiethanolamine, analytical standard
2,2'-(nitrosoimino)diethanol (n-nitrosodiethanolamine)
n-nitroso-diethanolamine
n-nitroso-bis(2-hydroxymethyl)-amine
Q26840926
T71599
EN300-7466693
2-[(2-hydroxyethyl)(nitroso)amino]ethan-1-ol
nitrosobis(2-hydroxyethyl)amine
n-nitroso-diethanolamine 100 microg/ml in methanol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" After cutaneous application NDELA was rapidly absorbed through the skin, and the absolute bioavailability was calculated to be 27% from blood data, and to be 32% (NDELA + ECMN) from urine data."( Kinetics and bioavailability of N-nitrosodiethanolamine after intravenous and cutaneous administration to rats.
Airoldi, L; Bonati, M; Bonfanti, M; Fanelli, R; Macri, A, 1984
)
0.55

Dosage Studied

ExcerptRelevanceReference
"A dose-response study of the carcinogenicity of N-nitrosodiethanolamine was conducted in F344 rats."( Dose-response study with N-nitrosodiethanolamine in F344 rats.
Lijinsky, W; Reuber, MD, 1984
)
0.83
" After topical application NDELA was slowly absorbed percutaneously, but once absorbed was distributed as in the orally dosed rats."( The fate of N-nitrosodiethanolamine after oral and topical administration to rats.
Brouwer, E; Lethco, EJ; Wallace, WC, 1982
)
0.64
" Because the dose-response curves were considered non-linear for most nitrosamines, synergistic effects were not apparent for the 1/4 mixture."( Effects of low dose mixtures of four N-nitroso compounds on hepatic foci development in the rat.
Futakuchi, M; Hasegawa, R; Hirose, M; Ito, N; Lijinsky, W; Shirai, T, 1996
)
0.29
" Blood levels of DEA reflected the dosing method used; oral greater than dermal with access greater than dermal without access."( Potential mechanisms of tumorigenic action of diethanolamine in mice.
Bartels, MJ; Brzak, KA; Mar, M; Markham, DA; Stott, WT; Thornton, CM; Zeisel, SH, 2000
)
0.31
" No NDELA was formed in rats repeatedly dermally dosed with TEA at the limits of detection in blood (0."( Investigation of the formation of N-nitrosodiethanolamine in B6C3F1 mice following topical administration of triethanolamine.
Bartels, MJ; Brzak, KA; Markham, DA; Saghir, SA; Stott, WT, 2005
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitroso compoundCompounds having the nitroso group, -NO, attached to carbon, or to another element, most commonly nitrogen or oxygen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.58490.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency31.62280.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency69.88110.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.99900.006038.004119,952.5996AID1159521
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.07950.000214.376460.0339AID588532
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency3.16230.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID226734Carcinogenic potency modelled in silico, (w = weak carcinogen)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-199071 (60.68)18.7374
1990's23 (19.66)18.2507
2000's17 (14.53)29.6817
2010's5 (4.27)24.3611
2020's1 (0.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.46 (24.57)
Research Supply Index4.81 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index38.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other118 (96.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]